Cabometyx and Opdivo show durable survival benefits in first-line advanced renal cell carcinoma

Press/Media

Period14 Feb 2023

Media coverage

1

Media coverage

  • TitleCabometyx and Opdivo show durable survival benefits in first-line advanced renal cell carcinoma
    Media name/outletPharma Marketletter
    Country/TerritoryUnited Kingdom
    Date14/02/23
    PersonsMauricio Burotto